Zhuangya Biotechnology develops macromolecular drugs targeting hemostasis, thrombosis, and oncology, focusing on therapies for rare diseases and cancer treatment. Their research includes recombinant coagulation factors and broad-spectrum anti-tumor agents, providing new therapeutic options for patients with bleeding disorders and cancer.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with hemophilia A, a common inherited bleeding disorder, require frequent infusions of coagulation factor VIII to prevent and control bleeding episodes. Current recombinant factor VIII products can be expensive, and some patients develop inhibitory antibodies, reducing treatment effectiveness. There is a need for more cost-effective and less immunogenic factor VIII therapies.
Solution
Zhuangya Biotechnology is developing recombinant coagulation factors, including a B-domain deleted human recombinant factor VIII (NX01), for the treatment of hemophilia A. NX01 is designed to be structurally similar to third-generation recombinant factor VIII products, potentially offering improved efficacy and reduced immunogenicity. The company is also researching broad-spectrum anti-tumor agents and therapies for other rare diseases, aiming to provide new therapeutic options for patients with limited treatment options.
Target Audience
The primary target audience includes patients with hemophilia A, individuals with rare bleeding disorders, and cancer patients seeking novel therapeutic options.
Features
- Recombinant human coagulation factor VIII (NX01) with a B-domain deletion
- Focus on hematology, oncology, and rare disease therapeutics
- Development of broad-spectrum anti-tumor agents
- Preclinical research on recombinant coagulation factor VIII (porcine sequence) in collaboration with Beijing Hua Fang Tian Shi Pharmaceutical
- Manufacturing processes for recombinant proteins